Company:  CTI BIOPHARMA CORP (CTIC)
Form Type:  DEF 14A
Filing Date:  7/27/2012 
CIK:  0000891293 
Address:  3101 WESTERN AVENUE
SUITE 600
 
City, State, Zip:  SEATTLE, Washington 98121 
Telephone:  (206) 282-7100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.22  
Change: 
0.05 (2.30%)  
Trade Time: 
Nov 21  
Market Cap: 
$333.20M
Description of Business
We are a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. We are primarily focused on commercializing PIXUVRI�(pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program of pacritinib for the treatment of myelofibrosis that will support regulatory submission for approval in the United States, or the U.S., and Europe.
Register for a Free Trial and access this filing in:     
  FORM DEF 14A
    Notice of Annual Meeting of Shareholders
    STATEMENT, SIGN AND DATE THE ITALIAN PROXY CARD, REQUEST A ...
    PROXY STATEMENT
    PROPOSAL 1
      NAME AND TITLE
    Shareholder Proposals
    Non-Employee Director Compensation Table
    PROPOSAL 2
    PROPOSAL 3
    PROPOSAL 4
    PROPOSAL 5
    REPORT OF THE AUDIT COMMITTEE
    EXECUTIVE COMPENSATION
      NAME AND TITLE
    Compensation Committee Report
    Compensation Committee Interlocks and Insider Participation
      COMPENSATION TABLE
    OTHER INFORMATION
    Security Ownership of Certain Beneficial Owners and Management
      BENEFICIAL OWNERS
      NAME AND TITLE
      Certain Transactions with Related Persons